Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis (MF)

The study will be conducted in 2 stages. Stage 1 will evaluate safety, tolerability, and efficacy of either KRT-232 (Arm 1) or TL-895 (Arm 2) in treatment naïve patients. Stage 2 will expand enrollment in Arm 1 and/or Arm 2 if expansion criteria is met.
Primary Myelofibrosis (PMF)|Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)|Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
DRUG: KRT-232|DRUG: TL-895
Spleen Volume Reduction (SVR), The proportion of subjects achieving ≥35% SVR at Week 24 by MRI/CT (central review), 24 weeks
Improvement in Total Symptom Score (TSS), The proportion of subjects who have at least a 50% reduction from Baseline to Week 24 in the total symptom score as measured by the MF-SAF v4.0, 24 weeks|Spleen Response Duration, Time from initial SVR of ≥35% by MRI/CT (central review) until progression, 48 months|Rate of conversion from RBC transfusion dependent to independent, The proportion of subjects who convert from transfusion dependent to transfusion independent at Week 24, 24 weeks|Overall Survival (OS), Time from first dose to death from any cause, 48 months|Progression free survival (PFS), Time from randomization to either first occurrence of disease progression or death due to any cause, 48 months
This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis (MF)

The study will be conducted in 2 stages. Stage 1 will evaluate safety, tolerability, and efficacy of either KRT-232 (Arm 1) or TL-895 (Arm 2) in treatment naïve patients. Stage 2 will expand enrollment in Arm 1 and/or Arm 2 if expansion criteria is met.